How does this help patients?

The current American Diabetics Association guidelines recommend an ACE inhibitor or ARB for diabetic patients with hypertension or microalbuminuria.¹

They recommend ACE inhibitors for all type 1 diabetic patients with hypertension and any degree of albuminuria or nephropathy, as well as type 2 patients with hypertension, microalbuminuria, or existing cardiovascular disease. 

In diabetic patients, multiple-drug therapy is generally required to achieve blood pressure targets. In addition, a recent systematic review and meta-analysis evaluating SBP lowering in adults with type 2 diabetes showed that each 10 mmHg reduction of SBP was associated with significantly lower risk of mortality, cardiovascular events, CHD, stroke, albuminuria, and retinopathy.²

1. American Diabetes Association. Diabetes Care Jan 2017, 40 (Supplement 1) S75-S87; DOI: 10.2337/dc17-S012

2. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood Pressure Lowering in Type 2 Diabetes A Systematic Review and Meta-analysis. JAMA. 2015;313(6):603-615. doi:10.1001/jama.2014.18574

How does the Gap Therapy: ACE/ARB Report help my pharmacy?

  1.  You get to fill additional ACEI & ARB scripts.
  2. Improved patient service leads to improved retention and word-of-mouth advertising
  3. While patients needing ACE Inhibitors or ARBs is no longer a pharmacy star rating measure (as of 2017) an thereby doesn't affect your DIRs directly, ACE/ARB adherence is being measured. Creating a pharmacy culture that prides itself on ACE/ARB expertise should empower your employees and customers to have conversations promoting ACE/ARB adherence throughout the community. If more people educated about the benefits of ACEIs and ARBs, residents and friends will naturally lower non-adherence rates among themselves. 

What's next?

Read about how to use the Gap Therapy: ACE/ARB Report here!

Did this answer your question?